Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?